Unlike mutation or copy loss, CRBN-Del-Exon10 splice variant was observed in newly diagnosed MM (NDMM) patients at ∼2.9% prevalence which increased to 29.6% in IMiD-resistant RRMM and was a prognostic biomarker for poor outcome in both disease settings (Gooding et al., 2021). Here, CRBN is linked to Miyoshi myopathy.